A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors
Latest Information Update: 25 Aug 2025
At a glance
- Drugs OBI 992 (Primary)
- Indications Gastric cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
Most Recent Events
- 08 Aug 2025 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2024 According to an OBI Pharma media release, Leia Tsimberidou MD, of MD Anderson Cancer Center in Houston, TX. USA is the lead investigator for the study.
- 12 Jun 2024 Status changed from planning to recruiting, according to an OBI Pharma media release.